(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of -15.22% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.58%.
Aclaris Therapeutics's revenue in 2026 is $15,742,000.On average, 9 Wall Street analysts forecast ACRS's revenue for 2026 to be $863,728,245, with the lowest ACRS revenue forecast at $212,356,668, and the highest ACRS revenue forecast at $1,501,231,632. On average, 6 Wall Street analysts forecast ACRS's revenue for 2027 to be $991,683,973, with the lowest ACRS revenue forecast at $424,713,337, and the highest ACRS revenue forecast at $1,501,231,632.
In 2028, ACRS is forecast to generate $1,022,128,985 in revenue, with the lowest revenue forecast at $424,713,337 and the highest revenue forecast at $1,501,231,632.